A Chinese Herbal Medicine for IBS-C

NCT06319729 | Not Yet Recruiting Phase 2

• 1 other identifier: REC/22-23/0659
• Study Type: interventional
• Target: 78
• Locations: 0 countries
• Sites: N/A

Brief Summary

This double-blind, placebo-controlled randomized pilot clinical trial will test the hypothesis that granules of CDD-2105, a Chinese herbal medicine formula, will have efficacy in alleviating constipation and abdominal pain in individuals with IBS-C. Participants (n=78) will be randomly assigned to the treatment or placebo group in a 1:1 ratio, followed by 4 weeks of intervention and 4 weeks of follow-up.

Conditions

Constipation-predominant Irritable Bowel Syndrome

Keywords

Chinese Herbal Medicine; IBS-C

Outcome Measures

Primary Outcomes (2)

• Abdominal Pain Responder Rate

  An abdominal pain responder is a patient who meets the abdominal pain weekly responder criterion (i.e., an improvement of ≥30% from the baseline weekly average of the worst abdominal pain in the past 24 hours score to the weekly average during the intervention, in at least 2 out of 4 weeks). Abdominal pain at its worst (in the last 24 hours) is assessed daily by participants on an 11-point numerical rating scale where 0 represents no abdominal pain and 10 represents very severe abdominal pain. Baseline of weekly abdominal pain will be the average between Week -2 and Week 0.

  from baseline to Week 4

• Complete Spontaneous Bowel Movement (CSBM) Responder Rate

  A CSBM responder is defined as a patient who meets the CSBM responder criterion (i.e., a mean increase of CSBM≥1/week compared with CSBM at baseline, in at least 2 out of 4 weeks). A spontaneous bowel movement (SBM) is defined as a bowel movement without laxative use in the preceding 24 hours. A CSBM is defined as a SBM that is associated with a sense of complete evacuation. Baseline of weekly CSBM will be the average between Week -2 and Week 0.

  from baseline to Week 4

Secondary Outcomes (9)

• Change in the weekly average self-assessed daily maximum abdominal pain scores (0-10)

  from baseline to Week 4

• Change in the number of days of abdominal pain per week

  from baseline to Week 4

• Change in the average weekly Complete Spontaneous Bowel Movement (CSBM) frequency

  from baseline to Week 4

• Change in the average weekly Spontaneous Bowel Movement (SBM) frequency

  from baseline to Week 4

• Change in the score of Irritable Bowel Syndrome-Severity of Symptoms (IBS-SSS) questionnaire

  from baseline to Week 4

Study Arms (2)

Treatment group

EXPERIMENTAL

During the 4-week intervention, participants are required to consume 4.7g of CDD-2105 granule (a Chinese herbal medicine formula containing four granular herbs) twice per day.

Drug: CDD-2105

Placebo group

PLACEBO COMPARATOR

During the 4-week intervention, participants are required to consume 4.7g of placebo twice per day.

Drug: Placebo

Interventions

CDD-2105 DRUG

A Chinese herbal medicine formula containing four granular herbs.

Treatment group

Placebo DRUG

Placebo

Placebo group

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• years adults
• Fulfill the clinically diagnosed with IBS-C based on the ROME IV criteria
• Abdominal pain intensity: weekly average of the worst daily (in the past 24 hours) abdominal pain score of ≥3.0 on a 0 to 10 point scale (based on the 2-week E-diary in screening)
• CSBM ≤ 2 times/week (based on the 2-week E-diary in screening)
• Understand and be able to follow written and oral instructions in Chinese
• Provide informed consent
• Able to use and complete 2-week E-diary for screening

You may not qualify if:

• Drug-induced or secondary causes of constipation
• Use of medications and/or supplements that may confound the study outcomes (including but not limited to antibiotics, steroid, analgesic drug, neuromodulator, prebiotics, symbiotics, or probiotics)
• Clinically significant colonoscopy or sigmoidoscopy examination findings after the onset of symptoms for patients who (1) is ≥50 years old; and/or (2) has family risk of colon-rectal cancer or familial polyposis syndromes; and/or (3) has alarm symptoms within 6 months before screening (unintentional weight loss: \>10% in 3 months, blood in the stools not caused by hemorrhoids or anal fissures, fever of unknown origin, anemia)
• Clinically significant laboratory or imaging findings within 6 months before screening
• Recent history of mushy or watery stools within one month
• Allergic to Chinese herbal medicine or G6PD
• Abdominal surgeries within the past year (except laparoscopic appendectomy)
• Pregnancy, breastfeeding or plan to become pregnant with the study timeframe
• Any disease(s), condition(s) or habit(s) deemed by the investigators that would compromise the individual's ability to complete the study, e.g. serious psychiatric conditions, at the discretion of the investigators
• Any disease(s), condition(s) or habit(s) deemed by the investigators that would prevent participation in the study, e.g. participation in past or active clinical research, at the discretion of the investigators

Sponsors & Collaborators

• Hong Kong Baptist University: lead

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: All the study drugs and placebo should be in the same package with the same drug appearance and blinded according to the randomized numbers of the subgroups. The specific blinding method is set as follows: the study drugs and placebo are uniformly packaged and numbered according to the corresponding randomized group results. One copy of the blinding letter in duplicate is sent with the test drug to the project leader of the test center for storage, and the other copy is kept by the pharmacy until the end of the trial.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prof.

Model Details: A double-blind, placebo-controlled randomized clinical trial

Study Record Dates

• First Submitted: March 13, 2024
• First Posted: March 20, 2024
• Study Start: March 25, 2024
• Primary Completion: August 31, 2024
• Study Completion: November 30, 2024
• Last Updated: March 21, 2024

Record last verified: 2024-03

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR
• Time Frame: 6 months
• Access Criteria: researchers' request